Compare Organon & Co. Common Stock (OGN) vs Trekor Metals Limited Common Shares (TGB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Trekor Metals Limited Common Shares — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Trekor Metals Limited Common Shares trades at $8.2 (market cap $3.12B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Trekor Metals Limited Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Trekor Metals Limited Common Shares for 4 Days on average.
| OGN | TGB | |
|---|---|---|
Market Cap | $3.62B | $3.12B |
Volume | 2,892,999 | 3,598,372 |
Sector | Health | Basic Materials |
52-Week High | $13.81 | $9.68 |
52-Week Low | $5.70 | $3.75 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $11.04B | $3.52B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TGB trades at $8.56, down 1.72% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue projected to grow from $673M in 2025 to $985M in 2026, turning from a net loss of $30M to a $16M profit. Recent copper production announcements highlight operational strength, though valuation metrics remain elevated with a P/E of 406.88. Analyst sentiment is mixed with a 25% buy rating amid balanced hold/sell recommendations.
The outlook for TGB hinges on copper production growth from Gibraltar and Florence mines, supporting revenue expansion and margin improvement. Key risks include execution challenges in mine ramp-ups, commodity price volatility, and high debt levels. While technical indicators suggest near-term upside, the stock's rich valuation requires careful monitoring of earnings delivery against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Trekor Metals Limited Common Shares
Trekor Metals is a mining company focused on copper. It operates the Gibraltar Mine and develops projects involving copper, gold, silver, and niobium.
Read more on TGB →
